TABLE 4:

Metabolite ratios from the posterior cingulate voxel in the 81 subjects, at 1.5 and 3 T

RatioTE1.5 T3 T
Cognitively Normal (n = 41)MCI (n = 20)AD (n = 20)Cognitively Normal (n = 41)MCI (n = 20)AD (n = 20)
NAA/Cr1351.77 (1.55–2.10)1.69* (1.45–1.80)1.65 (1.37–1.9)1.53 (1.22–2.15)1.49 (1.32–1.81)1.47 (1.13–1.61)
Cho/Cr1350.81 (0.53–0.99)0.87 (0.72–0.98)0.86 (0.72–1.06)0.70 (0.56–1.01)0.68 (0.53–0.83)0.66 (0.55–0.81)
NAA/Cr301.57 (1.39–1.71)1.51 (1.35–1.66)1.44 (1.22–1.60)1.50 (1.27–1.72)1.45 (1.31–2.27)1.40 (1.23–1.81)
Cho/Cr300.64 (0.56–0.77)0.68 (0.58–0.80)0.68 (0.56–0.84)0.63 (0.48–0.95)0.62 (0.53–0.81)0.65 (0.49–0.79)
MI/Cr300.66 (0.50–0.82)0.70 (0.59–0.78)0.74* (0.51–0.85)0.52 (0.38–0.66)0.51 (0.36–0.66)0.56 (0.36–0.73)
NAA/MI302.40 (1.88–3.26)2.22* (1.96–2.51)2.01 (1.48–2.84)2.88 (2.29–3.95)2.83 (2.02–4.19)2.63 (1.71–3.89)
Glu + Gln/Cr302.03 (1.46–2.62)1.91 (1.45–2.28)1.84 (1.34–2.46)
  • Note.—Data are the median. Numbers in parentheses are the range.

  • * P < .01 for comparison of ratios in patients with MCI or AD with those of cognitively normal subjects by using the rank sum test.

  • P < .001 for comparison of ratios in patients with MCI or AD with those of cognitively normal subjects by using the rank sum test.

  • P < .05 for comparison of ratios in patients with MCI or AD with those of cognitively normal subjects by using the rank sum test.